The UK's new car market experienced a 12.4% increase in March 2025, reaching 357,103 units, according to the Society of Motor ...

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the ...

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Summit Therapeutics (SMMT – Research Report) today. The company’s ...

We recently published a list of 10 Firms Buck Thursday’s Market Bloodbath. In this article, we are going to take a look at ...

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Summit Therapeutics (SMMT – Research Report) today. The company’s ...

Summit Therapeutics Inc.’s SMMT share price has surged by 5.60%, which has investors questioning if this is right time to sell.

Short interest in Summit Therapeutics Inc (NASDAQ:SMMT) increased during the last reporting period, rising from 21.22M to 23.77M. This put 19.96% of the company's publicly available shares short.

NASDAQ:SMMT opened at $20.60 on Wednesday. The stock has a market cap of $15.20 billion, a PE ratio of -73.57 and a beta of -1.04. The stock’s 50-day moving average is $20.49 and its two-hundred ...

Corebridge Financial Inc. decreased its holdings in Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) by 2.3% in the fourth quarter, according to its most recent filing with the Securities and ...

Fintel reports that on March 26, 2025, Citigroup upgraded their outlook for Summit Therapeutics (BMV:SMMT) from Neutral to Buy. Baker Bros. Advisors holds 24,425K shares representing 3.31% ...

MIAMI, February 24, 2025--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the ...